Literature DB >> 1868469

Tumor necrosis factor expression by human ovarian carcinoma in vivo.

H Takeyama1, N Wakamiya, C O'Hara, K Arthur, J Niloff, D Kufe, K Sakarai, D Spriggs.   

Abstract

Tumor necrosis factor (TNF) is a cytokine produced by monocytes and other cells with selective cytolytic activity against some but not all tumor cells. Cellular resistance to the cytolytic effects of TNF has been reported to be associated with autocrine production of TNF by the target cells. The purpose of this study was to determine whether or not human tumors produce tumor necrosis factor in vivo. Ovarian carcinoma tissue from 25 patients with ovarian carcinoma was examined for the presence of TNF. Four of 5 ascites fluid specimens and tissue sections of 16 of 20 patients were positive for TNF by immunoperoxidase staining. The source of the immunoreactive protein was further examined by in situ hybridization studies. TNF mRNA was detectable in each of the ascites specimens and 7 of 16 tissue sections that were positive by immunoperoxidase staining. These findings suggest that TNF is produced by some human tumors in vivo and that the association between TNF production and resistance to TNF antitumor action may be clinically relevant.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868469

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  [The demonstration of the radiation-induced production of tumor necrosis factor-alpha in Ewing's sarcoma RM 82 in vitro and in vivo].

Authors:  C Rübe; C Finke; F van Valen; K L Schäfer; B Dockhorn-Dworniczak; N Willich
Journal:  Strahlenther Onkol       Date:  1997-08       Impact factor: 3.621

2.  Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation.

Authors:  M L García-Hernández; R Hernández-Pando; P Gariglio; Jaime Berumen
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

3.  TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?

Authors:  Mamta Gupta; Ana Babic; Andrew H Beck; Kathryn Terry
Journal:  Hum Pathol       Date:  2016-04-08       Impact factor: 3.466

4.  Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.

Authors:  G Mantovani; A Macciò; R Versace; M Pisano; P Lai; S Esu; M Ghiani; D Dessì; E Turnu; M C Santona
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

5.  Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes.

Authors:  M J Maeurer; D M Martin; C Castelli; E Elder; G Leder; W J Storkus; M T Lotze
Journal:  Cancer Immunol Immunother       Date:  1995-08       Impact factor: 6.968

6.  Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models: comparison with the effects of tumour necrosis factor.

Authors:  S T Malik; N East; D Boraschi; F R Balkwill
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

7.  To NFκB or not to NFκB: The Dilemma on How to Inhibit a Cancer Cell Fate Regulator.

Authors:  Daniela Sorriento; Maddalena Illario; Rosa Finelli; Guido Iaccarino
Journal:  Transl Med UniSa       Date:  2012-10-11

8.  CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.

Authors:  Holger Bronger; Judith Singer; Claudia Windmüller; Ute Reuning; Daniela Zech; Claire Delbridge; Julia Dorn; Marion Kiechle; Barbara Schmalfeldt; Manfred Schmitt; Stefanie Avril
Journal:  Br J Cancer       Date:  2016-08-04       Impact factor: 7.640

9.  Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.

Authors:  Kristin L White; Robert A Vierkant; Catherine M Phelan; Brooke L Fridley; Stephanie Anderson; Keith L Knutson; Joellen M Schildkraut; Julie M Cunningham; Linda E Kelemen; V Shane Pankratz; David N Rider; Mark Liebow; Lynn C Hartmann; Thomas A Sellers; Ellen L Goode
Journal:  BMC Cancer       Date:  2009-06-06       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.